Research And Development
Biotechnology
Biopharmaceutical

BioCryst

$3.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-6.21%) Today
+$0.08 (2.41%) After Hours

Why Robinhood?

You can buy or sell BioCryst and other stocks, options, ETFs, and crypto commission-free!

About

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. Read More The company was founded in 1986 and is headquartered in Durham, NC.

Employees
100
Headquarters
Durham, North Carolina
Founded
1986
Market Cap
366.10M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
926.76K
High Today
$3.53
Low Today
$3.29
Open Price
$3.40
Volume
3.39M
52 Week High
$9.95
52 Week Low
$3.10

Collections

Research And Development
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Technology
US
North America

News

Seeking AlphaMay 24

BioCryst +2.4% as director buys 3,000 shares

BioCryst Pharmaceuticals (NASDAQ:BCRX) is up 2.4% in postmarket trading after an SEC filing indicating director Steve Aselage bought 3,000 shares.

429
Seeking AlphaMay 22

BioCryst Pharmaceuticals Is In A Very Tough Position After BCX7353 Phase 3 'Success'

The stock plunged more than 50% despite phase 3 success as the results were underwhelming and far inferior to Takeda's Takhzyro. BioCryst Pharmaceuticals (BCRX) announced that its phase 3 study of BCX7353 in HAE patients met the primary endpoint, but the stock lost more than half its value. The reason for the plunge despite the successful topline is simple – the results are deeply unsatisfying as BCX7353 has shown significantly worse efficacy than its approved competitor Takzhyro. BioCryst tried to tout so...

1,100
Yahoo FinanceMay 21

Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today

Tuesday was generally favorable on Wall Street, with the Dow Jones Industrial Average posting a triple-digit gain to wipe out some of its declines over the past couple of weeks.

5

Earnings

-$0.28
-$0.24
-$0.19
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.